CAMP4 Therapeutics, named for the camp closest to the top of Mount Everest, scaled closer to the peak of its solo mission Tuesday with $45 million in fresh capital.

Alentis Therapeutics wants to bring the first anti-fibrotic treatment to address underlying liver and kidney diseases into the clinic, and a new cash infusion of $67 million will help.

Money and high-profile names, they’re a double threat. Flagship Pioneering, the venture firm behind Moderna, snagged both during a busy Monday.

Kurome Therapeutics has raised $15 million to treat acute myeloid leukemia (AML) by targeting adaptive resistance mechanisms. Medicxi and Affinity Asset Advisors co-led the series A round to fund Kurome through IND-enabling studies.

Nearly a year after emerging from a Versant Ventures incubator, Bright Peak Therapeutics is reeling in a $107 million series B. The funding will advance Bright Peak’s pipeline of cytokine medicines toward the clinic and build out its underlying technology, though the company is keeping details close to the vest.

Flagship Pioneering united its “intersystems biology” efforts under one roof last fall, and, now, that company is gearing up for human trials. With a $55 million boost, Senda Biosciences will push three programs into the clinic in 2022, including treatments for chronic kidney disease and metabolic diseases as well as an asset aimed at making checkpoint inhibitors work for more people.

The conditional approval of Biogen’s Aduhelm (aducanumab) might have been controversial, but the FDA’s decision on Monday could spur a renaissance of sorts for the Alzheimer’s space after a “decade of a big hole.”

Synthekine scaled another rung on its quest to becoming a “category-defining cytokine company” with a $107.5 million series B A the preclinical company joins a crop of biotechs breaking into the cytokine space.

Alcyone Therapeutics hopes to be a standout star and rising goddess in the central nervous system (CNS) treatment landscape.

Another day, another SPAC deal. Three months after extending its crossover round to $300 million, Valo Health unveiled plans to go public by merging with a special purpose acquisition company formed by Khosla Ventures.